BigThink Forms Strategic Partnership with Boryung for Breast Cancer Treatment Drug... "Strengthening Anticancer Drug Lineup"

Amid active collaboration among major pharmaceutical companies, BigThink Therapeutics and Boryung (formerly Boryung Pharmaceutical) have signed a co-promotion agreement for breast cancer treatments. Boryung is the domestic company with the largest market share in the anticancer drug market. As a result, an increase in prescriptions of the new breast cancer drug Nerlynx® (active ingredient neratinib maleate) is expected.

According to BigThink and Boryung on the 3rd, the two companies have started strategic co-promotion this month for their breast cancer treatments, Nerlynx® and Pulvet (active ingredient fulvestrant), and plan to intensify joint sales and marketing efforts to expand both companies' anticancer drug pipelines.

BigThink's Nerlynx® is an oral epithelial growth factor receptor (HER)2-targeted anticancer agent, recommended by the NCCN (National Comprehensive Cancer Network) guidelines as a treatment for early and metastatic breast cancer, and is sold worldwide. It is notably the only extended adjuvant therapy proven to prevent and reduce recurrence and brain metastasis in HER2-positive early breast cancer.

Pulvet, marketed by Boryung, is an anti-estrogen agent (HER2-negative, hormone receptor-positive) prescribed alone or in combination for postmenopausal patients with advanced or metastatic breast cancer.

Through this strategic partnership, the two companies aim to leverage their sales and marketing capabilities to maximize synergy, securing anticancer drugs with new therapeutic positions in the breast cancer market, which is expected to grow at an average annual rate of over 3% until 2029.

Han Mi-kyung, Head of the Pharmaceutical Division at BigThink, stated, "We are collaborating with Boryung, which has an 'anticancer growth engine,' and from this year, we have started launching MUCOSAMIN®, used for the prevention and treatment of oral mucositis in cancer patients, together with Shinpung Pharmaceutical." She added, "We will accelerate our company vision of 'anticancer treatment ONE-STOP-SERVICE' and strive to achieve the first-ever annual sales of 10 billion KRW."